Properties and clinical utility of topotecan fluorescence: uses for retinoblastoma.
Topotecan fluoresces when exposed to ultraviolet (UV) light. Our observations with UV light in retinoblastoma cases has allowed us to minimise and manage inadvertent skin contact, guide periocular injections and leakage from such injections and document conjunctival contact after periocular injection in addition to demonstrating the drug in the vitreous after intravitreal injection. The technique is safe, inexpensive and easy to perform.
Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA Department of Ophthalmology, Weill Cornea Medical Center, New York, New York, USA.
Jasmine H
JH
Francis
Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA Department of Ophthalmology, Weill Cornea Medical Center, New York, New York, USA.
Brian P
BP
Marr
Unidad de Farmacocinética Clínica, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.
Paula
P
Schaiquevich
Pediatric Pharmacy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Michael G
MG
Kellick
Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA Department of Ophthalmology, Weill Cornea Medical Center, New York, New York, USA.
David H
DH
Abramson
D005451:Fluorescein Angiography / Q000379:methods*; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D019572:Retinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D012175:Retinoblastoma / Q000175:diagnosis / Q000188:drug therapy*; D059004:Topoisomerase I Inhibitors / Q000008:administration & dosage; D019772:Topotecan / Q000008:administration & dosage*; D014822:Vitreous Body / Q000473:pathology*
D059004:Topoisomerase I Inhibitors; D019772:Topotecan
Drugs; Imaging; Pharmacology; Treatment other; Vitreous